Cambridge Investment Research Advisors
MYGN icon

Cambridge Investment Research Advisors’s Myriad Genetics MYGN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,043
Closed -$699K – 2321
2018
Q4 		$699K Buy
24,043
+957
+4% +$34.4K 0.01% 1128
2018
Q3 		$1.06M Buy
+23,086
New +$1.03M 0.01% 994

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors's MYGN Position: Q1 2019 in Review

Cambridge Investment Research Advisors sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 24,043 shares — an estimated $699K sold.

Cambridge Investment Research Advisors first reported a position in MYGN in Q3 2018 and held it in 2 quarters. The position peaked at $1.06M in Q3 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

  • Cambridge Investment Research Advisors reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 24,043 Myriad Genetics shares in Q1 2019, an estimated $699K.
  • Cambridge Investment Research Advisors first reported a position in Myriad Genetics in Q3 2018 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Myriad Genetics position peaked at $1.06M in Q3 2018.
  • 262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2019, filed 8 May 2019.